<DOC>
	<DOCNO>NCT00303810</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy different way give together one drug ( combination chemotherapy ) may kill tumor cell . It yet know radiation therapy combination chemotherapy regimen effective treat medulloblastoma , supratentorial primitive neuroectodermal tumor ( PNET ) , ependymoma . PURPOSE : This clinical trial study six different radiation therapy combination chemotherapy regimens compare well work treat young patient medulloblastoma , PNET , ependymoma .</brief_summary>
	<brief_title>Radiation Therapy Combination Chemotherapy Treating Young Patients With Medulloblastoma , Supratentorial Primitive Neuroectodermal Tumor , Ependymoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare prognosis , use adapt risk stratification quality control diagnostic assessment therapy , pediatric patient intracranial medulloblastoma , supratentorial primitive neuroectodermal tumor ( PNET ) , ependymoma treat intensified chemotherapy radiotherapy . - Determine effect omission radiotherapy , term long-term sequela , young child medulloblastoma hyperfractionation reduction radiotherapy old child medulloblastoma . - Compare hyperfractionated radiotherapy reduced-dose radiotherapy old child stage M0 medulloblastoma . OUTLINE : This multi-protocol study . Patients enrol 1 6 treatment protocol accord diagnosis age diagnosis . - Protocol HIT-2000-AB4 ( ≥ 4 year old diagnosis nonmetastatic medulloblastoma ) ( phase III randomize control multicenter study ) : Patients randomize undergo hyperfractionated radiotherapy conventional reduced-dose radiotherapy , follow vincristine , lomustine , cisplatin . - Protocol HIT-2000-BIS4 ( &lt; 4 year old diagnosis nonmetastatic medulloblastoma ) : Patients receive 5 course cyclophosphamide , vincristine , methotrexate , carboplatin , etoposide phosphate , intrathecal methotrexate . Patients residual tumor 3 course undergo conventionally fractionate reduced-dose radiotherapy . - Protocol MET-HIT-2000-AB4 ( ≥ 4 year old diagnosis metastatic medulloblastoma supratentorial PNET ) : Patients receive combination chemotherapy HIT-2000-BIS4 2 course . Patients undergo hyperfractionated radiotherapy receive combination chemotherapy HIT-2000-AB4 . Patients good response combination chemotherapy ( HIT-2000-BIS4 ) also receive high-dose chemotherapy . - Protocol MET-HIT-2000-BIS4 ( &lt; 4 year old diagnosis metastatic medulloblastoma supratentorial PNET ) : Patients receive 2-4 course carboplatin IV etoposide phosphate IV continuously 96 hour . Patients partial complete response also receive high-dose carboplatin , etoposide phosphate , cyclophosphamide , thiotepa . Patients residual tumor undergo conventional fractionate , reduced-dose radiotherapy . - Protocol E-HIT-2000-AB4 ( ≥ 4 year old diagnosis intracranial ependymoma ) : Patients undergo local hyperfractionated radiotherapy . If histological grading show WHO grade III tumor , patient also receive 5 course vincristine , cyclophosphamide , carboplatin , etoposide phosphate . - Protocol E-HIT-2000-BIS4 ( &lt; 4 year old diagnosis intracranial ependymoma ) : Patients receive 5 course cyclophosphamide , vincristine , methotrexate IV , carboplatin , etoposide phosphate undergo conventional fractionated local radiotherapy . PROJECTED ACCRUAL : A total 567 patient accrue study .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Medulloblastoma Supratentorial primitive neuroectodermal tumor ( PNET ) Ependymoma Intracranial tumor No brain stem tumors No recurrent relapse tumor PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
</DOC>